Atopic eczema

This trial tests whether an experimental antibody called 611, given as a shot alongside a topical corticosteroid, can improve moderate-to-severe atopic dermatitis (eczema) better than the steroid alone. Adults aged 18 to 75 with a history of inadequate response to topical treatme…

Researchers are testing an experimental ointment called IN-A002 for mild to moderate atopic dermatitis, a common skin condition that causes itchy, inflamed skin. The trial enrolls healthy adult men and adults with atopic dermatitis to see how safe and tolerable the ointment is wh…

Researchers are testing an experimental monoclonal antibody called OpSCF in adults with moderate to severe atopic dermatitis, also known as eczema. About 50 participants receive either OpSCF or a placebo injection every two weeks for 14 weeks. The main goal is to measure how much…

This Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new wa…

This trial tests whether the probiotic Lactobacillus rhamnosus GG can ease atopic dermatitis, a chronic skin condition causing dry, itchy patches, in children aged 6 to 36 months. Half of the 100 participants receive the probiotic daily, while the other half get a placebo. Resear…

This study tested a drug called rocatinlimab in 532 teenagers with moderate-to-severe eczema that didn't improve with standard creams. The goal was to see if the drug could clear skin and reduce itching over 24 to 52 weeks. Participants received either the drug or a placebo, and …

Researchers are testing LT-002-158, an oral drug that degrades IRAK4, a protein involved in inflammation. This first-in-human trial gives the drug to healthy volunteers to check its safety, tolerability, and how the body processes it. The study also looks at how food affects drug…

This early-stage trial is testing whether an experimental drug called SHR-1819, given as a weekly injection, is safe and tolerable for adults with moderate-to-severe atopic dermatitis (a common form of eczema). The study will also look at how the drug moves through the body and w…

This study tests a drug called lebrikizumab against a placebo in 221 adults and teenagers with moderate-to-severe hand and foot eczema. The treatment is given as an injection under the skin over 16 weeks. The main goal is to see if the drug can clear or nearly clear the skin rash…

This phase 2 trial is investigating whether CM310, an experimental biologic given by injection, can safely and effectively control moderate-to-severe atopic dermatitis (eczema) over the long term. The study enrolls adults aged 18 to 75 with the condition and will track side effec…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works …

This study will follow about 1,000 adolescents and adults in China who are prescribed upadacitinib for moderate to severe atopic dermatitis (eczema). Researchers will track how patients use the medication, any dose changes, and how well they stick to their treatment over 12 month…

This study tested a new drug called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't controlled by creams. The trial included 643 participants and compared amlitelimab to a placebo, while ever…

This Phase 3 study tests amlitelimab, an injected drug, in 589 people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The goal is to see if amlitelimab can clear or nearly clear the skin and reduce eczema seve…

This study tested a new medicine called rocatinlimab, given as an injection, for adults with moderate-to-severe eczema that wasn't well controlled with standard creams. About 746 participants received either the study drug or a placebo, along with topical treatments. The goal was…

This study tested a drug called tralokinumab for people with moderate-to-severe atopic hand eczema that hasn't improved with standard treatments. 235 adults received either the drug or a placebo every two weeks for 16 weeks, then everyone got the drug for another 16 weeks. The go…

This study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, along with standard topical steroids. The…

This trial tests whether a topical ozonated vegetable oil can reduce the severity of mild-to-moderate atopic dermatitis (eczema) in children aged 1 month to 6 years. Over 14 days, researchers compare the oil against a placebo, measuring changes in a standard eczema severity score…

This phase II trial is testing whether an experimental drug called MG-K10 can reduce the severity of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. About 60 adults who have not responded well to topical treatments will receive either MG-K10 or a plac…

This pilot study tests whether a modified Chinese herbal formula, Modified Huang-Lian-Jie-Du Decoction (MHLJDD), can reduce eczema symptoms in children aged 4 to 17. Participants take either the herbal granules or a placebo twice daily for 12 weeks. The study measures changes in …

This study tested a drug called rocatinlimab in 187 teenagers aged 12 to 17 with moderate-to-severe eczema that didn't respond well to standard creams. The goal was to see if the drug is safe and tolerable over 52 weeks. Participants received regular injections, and researchers t…

This study tested a new medication called rocatinlimab for adults with moderate-to-severe eczema (atopic dermatitis). About 769 people took part to see if the drug can clear skin and reduce itching better than a placebo. The goal is to provide a new treatment option for those who…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that didn't get better with creams or other treatments. The goal was to see if it can clear or nearly clear the skin and reduce itching…

This early-phase trial tested a new biologic drug called UCB1381 in 109 people, first in healthy volunteers and then in those with moderate to severe atopic dermatitis (eczema). The goal was to check safety and see if it improves eczema symptoms. Participants received either the …

This study tests whether lebrikizumab, an injectable biologic, can improve skin symptoms in adults and adolescents (aged 12 and older) with moderate-to-severe atopic dermatitis, also known as eczema. Participants receive lebrikizumab for 24 weeks, and doctors measure changes in e…

This study tests an experimental oral medication called QY201 in adolescents aged 12 to 17 with moderate to severe atopic dermatitis (eczema). Participants take either 10 mg or 20 mg of QY201 twice daily for 28 days. The main goal is to understand how the drug moves through the b…

This phase 2 study tests whether rilzabrutinib, an oral medication, can reduce eczema severity in adults with moderate-to-severe atopic dermatitis who do not respond well to or cannot tolerate topical corticosteroids. Participants receive either rilzabrutinib or a placebo for 16 …

This study tests an experimental drug called SHR-1819 in children and adolescents aged 6 to 17 with moderate-to-severe atopic dermatitis (a type of eczema). The main goal is to check the drug's safety and how the body processes it. Researchers will also look at changes in skin-re…

This study tests a new antibody drug called 611 in 124 Chinese children and adolescents aged 6 to 18 with moderate to severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation. The main goals are to check safety and how the drug moves through the body…

This phase 3 study tested a drug called rocatinlimab in 726 adults with moderate-to-severe atopic dermatitis (eczema) that wasn't well controlled by creams. Participants received either the drug or a placebo as a shot under the skin for 24 weeks. The main goals were to see if the…

This study tested a drug called nemolizumab in 109 children aged 2 to 11 with moderate-to-severe eczema. The drug is given as a shot under the skin every 4 weeks for a year. Researchers measured how the drug moves through the body, its safety, and whether it improves eczema sympt…

This study tested a new drug called BGB-45035 for the first time in humans. It looked at safety in healthy volunteers and then in people with autoimmune skin diseases like atopic dermatitis (eczema) and prurigo nodularis (a condition causing intensely itchy bumps). The goal was t…

This study tested a daily pill called upadacitinib in 912 teens and adults with moderate to severe eczema (atopic dermatitis) that was not well controlled with creams. Participants received either the study drug or a placebo for 16 weeks. The main goals were to see if the drug co…

This completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…

This study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track seri…

This study looked at whether nemolizumab, a drug for moderate-to-severe eczema, interferes with the body's ability to respond to tetanus and meningococcal vaccines. 242 adults and teens with eczema received either nemolizumab or a placebo, plus the vaccines. The goal was to see i…

This study looked at how the drug abrocitinib affects the skin barrier in 20 adults with moderate to severe atopic dermatitis (eczema). Researchers measured water loss from the skin and changes in skin-related genes at 2 and 12 weeks. The goal was to see if the treatment helps re…

This study tested an oral medication called upadacitinib in 912 teenagers and adults with moderate to severe eczema (atopic dermatitis) who needed stronger treatment. Participants received either the drug or a placebo for 16 weeks. The main goals were to see if the drug could sig…

This study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of lif…

This study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who completed a previous year-long study could join this 2-year extension. The main goal was to see how many people st…

This study followed 305 Canadian adults and children (ages 6+) with moderate-to-severe eczema who were prescribed Dupixent as part of their routine care. Researchers measured how many patients achieved at least a 75% reduction in eczema severity after 6, 12, and 18 months. The go…

This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe. Children received injections over several weeks and used moisturizers daily. The trial is complete, …

This study tested an ointment called RSS0393 in 168 adults with mild to moderate atopic dermatitis (eczema). Participants used different strengths of the ointment or a placebo for a set period. The goal was to see if the ointment could clear or nearly clear the skin rash. Results…

This study tested a new drug called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (a type of eczema). Participants received one of three doses of the drug or a placebo. The main goal was to see if the drug could reduce eczema severity by at least 75% after 16 w…

This study tested two creams for mild to moderate eczema in 40 children aged 1-12. One cream was a steroid (fluticasone), the other a non-steroid (crisaborole). Both were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments w…

This study tested whether a moisturizer containing postbiotic Saccharomyces and Lactobacillus can reduce the risk of eczema returning in children aged 0-6 years who are in remission. 98 children used either the special emollient or a standard one for 12 weeks. The goal was to see…

This study tested a biologic drug called SIM0718 in 259 adults and teens with moderate to severe atopic dermatitis (eczema) that did not respond well to creams. Participants received either the drug or a placebo every two weeks for 16 weeks. The goal was to see if the drug could …

This completed Phase 2 trial tested a new ointment called CGB-500 (containing tofacitinib) against an approved cream (ruxolitinib) for atopic dermatitis, a type of eczema. Only 3 people aged 12 and older took part, applying both treatments to different skin areas twice daily for …

This study tested whether teenagers and adults with moderate-to-severe eczema (atopic dermatitis) could successfully give themselves injections of the drug rocatinlimab at home using special devices. The main goal was to see how many full doses were self-administered correctly up…

This study tested a new drug, AK120, in 450 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check for side effects and see how well the drug works. Researchers measured changes in eczema severity using standard skin scores.

This study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal …

This study tested the drug lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug is safe and helps clear skin. Participants received injections over 24 weeks, and doctors measured improvement using a standard ec…

This study looked at the long-term safety of the drug SHR-1819 in 79 adults with moderate to severe eczema who had already taken part in earlier studies of the same drug. Researchers tracked side effects and how well the drug controlled the disease over time. The goal was to see …

This study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational…

This study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% im…

This study tested a new medicine called LEO 138559 (Temtokibart) in 262 adults with moderate-to-severe atopic dermatitis (eczema). Participants received one of four doses or a placebo as injections under the skin for 16 weeks. The goal was to see how well the drug reduces eczema …

This study looked at how safe and effective upadacitinib is for Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Over 2,300 adults took the drug as prescribed by their doctor and were followed for about 28 weeks. Resear…

This study tested a daily pill called abrocitinib in 82 adults with moderate to severe chronic hand eczema that did not get better with steroid creams. The goal was to see if the drug could reduce skin redness, scaling, and other symptoms. Researchers also checked for side effect…

This study tested the safety and effectiveness of abrocitinib, a daily pill, for people aged 12 and older with moderate to severe eczema. Participants took either 100 mg or 200 mg of abrocitinib for up to 92 weeks, with some continuing until the drug became commercially available…

This Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance a…

This study tested whether a cream containing N-acetyl cysteine (NAC) could improve mild-to-moderate eczema better than plain cold cream. One hundred people with eczema used either the NAC cream or a placebo cold cream. Researchers measured changes in skin bacteria (Staph) and ecz…

This Phase 2 trial tested an experimental oral drug called SCD-044 in 250 adults with moderate to severe atopic dermatitis (eczema). Participants received one of three doses of SCD-044 or a placebo for 16 weeks. The main goal was to see if the drug could reduce eczema severity by…

This study looked at the long-term safety of a cream called roflumilast for people with mild to moderate eczema (atopic dermatitis). Over 1,200 participants, ages 2 and up, applied the cream once daily for up to 52 weeks. The main goal was to track any side effects, with secondar…

This study tested whether baricitinib (a newer pill) works better than azathioprine (an older pill) for adults with moderate-to-severe eczema. Both groups also used steroid creams. The goal was to see which combination reduces skin redness, thickness, and itching more effectively…

This study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…

This completed Phase 3 trial tested a Chinese herbal formula called Xiao-Xian-Gui-Fu-Tang in 19 people aged 6 to 30 with moderate to severe atopic dermatitis (eczema). Participants took the herbal blend or a placebo for several weeks. Researchers measured changes in eczema severi…

This study tested the long-term safety and effectiveness of lebrikizumab, a drug for moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already taken the drug in earlier studies were followed for up to 33 months. The goal was to see how well the drug c…

This Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score…

This study compared an online, team-based care model to standard in-person care for managing atopic dermatitis (eczema). 300 patients were randomly assigned to either online or in-person care for 12 months. The goal was to see if the online approach could match in-person care in …

This study tested an experimental drug called LW402 in 144 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itching. Participants received either the drug or a placebo, and doctors measured skin impro…

This study tested a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The drug is a lab-made antibody that blocks a key protein involved in inflammation. The goal was to see if it improves skin clearing and reduces itch compared to a place…

This study tested whether methotrexate, an older drug used for arthritis, works as well as cyclosporine for people with moderate to severe atopic dermatitis (eczema). One hundred adults received either drug for 24 weeks. The main goal was to see if eczema severity dropped by half…

This early-stage trial tests a new drug called CM512 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug. 110 participants will receive either CM512 or a placebo, and researchers w…

This Phase 3 study tested MH004 ointment in 375 adolescents and adults with mild to moderate atopic dermatitis (eczema). Participants applied the ointment or a placebo twice daily for 4 weeks, followed by a 44-week safety extension. The main goals were to see if the ointment coul…

This study tested whether dupilumab, an injected drug for eczema, improves skin barrier function in 52 people with moderate to severe atopic dermatitis. Researchers measured water loss from the skin after tape stripping to assess barrier repair over 16 weeks. The goal was to see …

This study tested a new drug, camoteskimab, in 62 adults with moderate to severe eczema (atopic dermatitis). Participants received either the drug or a placebo for 16 weeks, followed by an open-label extension where everyone could get the drug. The main goal was to see if camotes…

This study looked at how dupilumab, an injectable biologic drug, affects the skin barrier in 41 children aged 6 to 12 with moderate to severe atopic dermatitis (eczema). Researchers measured water loss through the skin after removing thin layers with tape to assess barrier functi…

This study tested the drug dupilumab (Dupixent) in 44 Chinese patients aged 12 to 65 with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug improves skin barrier function by measuring water loss through the skin over 16 weeks. Participants received du…

This study tested the drug dupilumab (given as a shot) plus steroid creams in 62 Japanese children aged 6 months to 18 years with moderate-to-severe eczema that wasn't controlled by other treatments. The goal was to see if dupilumab could improve skin symptoms and itching over 16…

This study tested a cream called tapinarof in 406 people aged 2 and older with moderate to severe eczema. Participants applied the cream or a placebo once daily for 8 weeks. The main goal was to see if the cream could make skin clear or almost clear. Results are being analyzed to…

This early-stage trial tested an experimental drug called IBI356 in 99 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check if the drug is safe and how the body processes it. Participants received either a single dose, multiple doses, or a pla…

This study tested whether an artificial intelligence tool called Legit Health Plus can help doctors track the severity of chronic skin conditions like acne, psoriasis, and eczema from a distance. 160 participants used a smartphone app for 6 months to take photos of their skin and…

This study tested a new treatment called STMC-103H in 283 newborn babies and infants who are at high risk for developing allergies (like eczema or food allergies) because of their family history. The goal was to see if the treatment is safe and can prevent these allergic conditio…

Researchers are testing whether an investigational eyelid emollient balm improves comfort and tolerance when used with tacrolimus 0.1% ointment in adults with atopic eyelid dermatitis. The study enrolls 33 people aged 18 to 65 with eczema on both eyelids. Each person applies the …

This early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored fo…

This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visi…

This trial is testing whether a bio-natural moisturizing cream, called SaaTwae, can safely ease symptoms of mild-to-moderate atopic dermatitis (eczema) in children and adults. Participants will apply the cream or a placebo to affected skin twice daily, and researchers will track …

This trial tests whether a cream containing hyaluronic acid, peptides, and plant extracts can improve skin barrier function and ease symptoms in people with atopic dermatitis (eczema). Participants, aged 2 and older, will use the cream alongside their usual topical corticosteroid…

This study tests a moisturizing lotion made with Edelweiss extract, macadamia oil, and shea butter in 15 adults with mild-to-moderate eczema. Over 4 weeks, doctors will check skin redness, dryness, and severity, and participants will report any side effects. The goal is to see if…

This study tests whether a daily supplement called NPQ Plus can improve skin health, antioxidant status, fatigue, and well-being in healthy adults with minor skin concerns like dryness or itchiness. The supplement contains polyphenols, NMN, PQQ, CoQ10, and minerals. Participants …

This early-stage trial tests whether HL-300 ointment is safe and tolerable when applied to the skin of healthy adult volunteers. Researchers will give single or multiple doses of the ointment or a placebo to 36 participants aged 18 to 45 in China. The study monitors for side effe…

This study tested whether a supplement containing L-histidine, along with a topical oil or lotion and unscented soap, could improve mild-to-moderate eczema in children. Forty children ages 1 to 12 were split into two groups: one received a powder supplement and the other a gummy …

This phase 2 trial tested a gel called HY209 on 210 adults with mild to moderate atopic dermatitis (eczema). The study compared different strengths of the gel to a placebo to see if it could reduce skin redness, itching, and rash. Results will show whether the gel is safe and eff…

This study tested a cream containing ruxolitinib on 241 adults with moderate atopic dermatitis (eczema) who had not gotten better with standard steroid creams. The goal was to see if the cream could improve skin clearing and reduce itching. The trial is now complete, and results …

This pilot study tested whether adding group psychotherapy to standard care can help adults with moderate-to-severe atopic dermatitis (eczema). Thirty-two participants were assigned to either standard care alone, standard care plus stress management and resilience training, or st…

This study tested a special moisturizing cream containing a friendly bacteria called Lactobacillus reuteri to see if it could improve eczema symptoms in children. Forty children aged 6 months to 12 years with mild-to-moderate eczema used the cream for 8 weeks. Researchers measure…

This study looked at whether adding vitamin K2 to standard treatment could improve symptoms in children aged 6–12 with moderate-to-severe atopic dermatitis (eczema). For 12 weeks, 100 children received either vitamin K2 or a placebo alongside their usual care. The main goal was t…

This study tested an experimental drug called lunsekimig in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants received one of three doses of the drug or a placebo as a shot under the skin for 24 weeks. The main goal was to see if the drug reduces eczema …

This Phase 2 trial tested a cream called VC005 on 118 adults with mild to moderate atopic dermatitis (eczema). The study compared the cream to a placebo to see if it safely reduces eczema symptoms like itching and skin redness. Results will help decide if larger studies are warra…

This early-stage study tested a cream called VC005 in 11 adolescents aged 12 to 18 with mild to moderate eczema. The main goal was to check safety and how the body processes the drug. Researchers measured drug levels in the blood and looked for side effects.

This study tested a special cream containing a butyrate releaser (a substance that helps the skin barrier) in 100 children aged 6-36 months with eczema. The cream was compared to a standard moisturizer over 12 weeks. The goal was to see if it could reduce eczema severity and impr…

This study tested an experimental oral drug called LNK01001 against a placebo in 356 adults with moderate to severe atopic dermatitis (eczema) who had not responded well to creams or other treatments. The goal was to see if the drug could improve skin clearing and reduce itching …

This study tested a new drug called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The goal was to check its safety and see if it can improve eczema symptoms. The trial involved 107 participants and compared the drug to a placebo.

This study tested a new ointment called CGB-500, which contains the drug tofacitinib, for treating eczema (atopic dermatitis) in 180 people aged 12 and older. Participants applied the ointment or a placebo daily for 8 weeks. The goal was to see if it safely reduces skin redness, …

This early-stage trial tested a new oral drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). Participants took the drug once daily for 28 days and had weekly checkups. The main goal was to see if the drug is safe and tolerable, while also looking f…

This early-stage trial tested an experimental drug called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and tolerability, while also looking for signs of symptom improvement. Participants received either the drug o…

This study tested whether a measles vaccine could help control eczema (atopic dermatitis) in adults. Researchers gave 20 adults with moderate-to-severe eczema either the measles vaccine or a placebo and tracked their symptoms for 45 days. The goal was to see if the vaccine could …

This early-stage study tested an oral medication called KT-621 in 22 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and how the body processes the drug. Researchers monitored side effects and drug levels in the blood, but did not meas…

This study tested an experimental ointment called LNK01004 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Participants applied the ointment twice daily for 8 weeks. The goal was to see if it reduces skin redness, swelling, and itching better than a placebo ointm…

This study tested whether a daily probiotic called Bifidobacterium longum CCFM1029 can reduce eczema symptoms in infants aged 3 months to 3 years. One hundred children with atopic dermatitis were split into two groups: one received the probiotic and the other a placebo for 3 mont…

This study tested whether a new oral medicine called TAU-284 (bepotastine besilate) can reduce itching in children aged 7 to 15 with atopic dermatitis (eczema). Over 300 children took either TAU-284 or an older medicine (ketotifen) twice daily for several weeks. The main goal was…

This 56-day study tested a cream containing CBD and cherimoya fruit extract on 42 children and adults with mild-to-moderate atopic dermatitis (eczema). Participants applied the cream twice daily. Researchers measured skin redness, dryness, itching, and sleep quality. The goal was…

This study tested a cream called ARQ-151 on 652 children aged 2 to 5 with eczema (atopic dermatitis). The cream was applied once daily for 4 weeks. The goal was to see if it could clear or nearly clear the skin rash better than a cream with no active ingredient. The study is comp…

This study tested a new ointment called YR001 in 35 adults with mild to moderate atopic dermatitis (eczema). The main goal was to check if the ointment is safe and how the body processes it. Researchers also looked at whether it improves skin condition. The trial was completed an…

This Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. The drug is being developed for asthma, COPD, and atopic dermatitis. Participants received either the drug or a placebo by IV infusion, and researchers monitored side effects …

This study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to 2 years with mild-to-moderate eczema. The main goal was to see if the cream is safe and well-tolerated. Researchers tracked side effects, serious side effects, and …

This early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Rese…

This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin seve…

This study tested a behavioral therapy called EMD-U in 96 adults with atopic dermatitis or prurigo nodularis who had a strong urge to scratch. The therapy involves focusing on the itchy spot while moving the eyes, repeated until the urge fades. Researchers compared EMD-U plus usu…

This study tested an experimental drug called BSI-045B in 22 adults with moderate to severe atopic dermatitis (eczema). Participants received injections weekly for 4 weeks, then every 2 weeks up to 24 weeks. The main goals were to see if the drug safely reduces eczema severity by…

This study tested a high-SPF sunscreen on 42 adults with mild to moderate atopic dermatitis (eczema). Over 22 days, doctors checked how well the skin tolerated the sunscreen and if it helped protect the skin barrier. The goal was to see if the product is safe and comfortable for …

This study tested a broad-spectrum SPF50+ sunscreen on 22 children with mild-to-moderate atopic dermatitis (eczema). The goal was to see how well the children's skin tolerated the sunscreen when applied at least twice daily. Doctors rated tolerance as excellent, very good, good, …

This study tested an ointment called MH004 in 160 healthy volunteers and people with mild to moderate atopic dermatitis (eczema). The goal was to check safety and how well it reduces skin symptoms like redness and itching. The ointment was applied to the skin daily for several we…

This early-stage trial tested an experimental antibody injection called BSI-045B in 54 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check safety and tolerability, with some early looks at how well it might control symptoms. The study is comp…

This study tested whether dupilumab, an injectable drug that reduces inflammation, can improve sleep quality in adults with moderate-to-severe atopic dermatitis (eczema). 188 participants received either dupilumab or a placebo. The main goal was to measure changes in sleep qualit…

This study tested a new topical gel called PRN473 (SAR444727) in 39 adults with mild to moderate atopic dermatitis (eczema). Each participant had two similar patches of eczema treated: one with the study gel and one with a placebo gel, without knowing which was which. The main go…

This study tested a cosmetic cream in 21 women with mild to moderate atopic dermatitis (eczema). Participants applied the cream daily for up to 31 days. Researchers measured skin severity, itching, sleep quality, and skin hydration. The goal was to see if the cream could help eas…

This study tested a cream called tapinarof in 36 children aged 2 to 17 with severe eczema covering large areas of skin. The goal was to see how much of the drug gets into the body and whether it is safe. Children applied the cream once daily, and researchers monitored side effect…

This study tested a cream called tapinarof on 407 people aged 2 and older with moderate to severe eczema (atopic dermatitis). Participants applied the cream or a placebo once daily for 8 weeks. The goal was to see if the cream could clear or nearly clear the skin rash better than…

This phase 3 trial tested a once-daily cream called roflumilast (0.15%) in 354 people aged 6 and older with mild to moderate atopic dermatitis (eczema). Participants applied the cream or a placebo for 4 weeks. The main goal was to see if the cream could make skin clear or almost …

Researchers are studying whether a non-invasive skin imaging technique called reflectance confocal microscopy can predict how well people with moderate to severe atopic dermatitis respond to dupilumab. The trial enrolls 40 participants aged 6 months and older who are starting dup…

This completed study followed 945 people, mostly children and young adults with severe eczema or related allergic conditions, along with their relatives. Researchers observed how these diseases progress over up to a year, using tests like allergy skin pricks, blood draws, and lun…

This study looks at how a new medicine (PF-08049820) is processed by the body when taken alone or with another drug (rabeprazole). It involves 18 healthy Chinese adults aged 18-65. Participants take both medicines by mouth, and blood samples are collected to measure drug levels. …

This study looks at how a new medicine called PF-08049820 changes the way birth control pills, a sedative, and a blood thinner move through the body. It involves 16 healthy adult women who will take the drugs alone and then with PF-08049820. The results will help plan future stud…

This early-stage study tests the safety of PF-08049820, a medicine being developed for eczema (atopic dermatitis), in about 71 healthy adults. Participants will take single or multiple doses of the drug or a placebo, and researchers will monitor how the body processes it and whet…

This study investigates whether compounds found in ultra-processed foods, like advanced glycation end products (AGEs), might play a role in childhood eczema, also known as atopic dermatitis. Researchers will compare the diets of 100 children aged 6 months to 10 years, half with e…

This early-stage study tests a new drug called SHR-1819 in 160 healthy adults to see how it enters the body when given with different injection devices. The goal is to compare the drug levels and safety between devices, not to treat any disease. Participants must be 18-55 years o…

This study looked at how well vaccines work in adults with moderate-to-severe eczema who are taking amlitelimab, an experimental drug. About 224 participants received either amlitelimab or a placebo along with tetanus and pneumonia vaccines. The goal was to see if the drug change…

This study will use a special headband that reads brain waves to see how adults with mild to moderate atopic dermatitis (eczema) respond to a single application of a marketed cream compared to plain water. Twenty participants will have their brain activity measured for signals re…

This study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. About 221 adults with eczema received either the drug or a placebo, then got tetanus and meningococcal vaccines. The goal was to see if the drug lowers the body's abil…

This study looks at children with eczema (atopic dermatitis) that is not well controlled by prescription creams or for whom such creams are not advised. Researchers are collecting blood and cheek swab samples to find biological markers (biomarkers) that may be linked to how the d…

This study looks at how taking VC005 tablets with or without food changes the drug's levels in the blood. It involves 30 healthy adults aged 18 to 45. The goal is to gather information to help design future studies for atopic dermatitis (eczema). Participants will take the drug t…

This study looked at the genes in the skin of 433 people with eczema (atopic dermatitis) to find patterns that separate mild from severe cases. Researchers collected skin samples and tracked how these patterns changed with standard treatments like steroid creams and dupilumab. Th…

This study looked at how adults with moderate-to-severe atopic dermatitis (eczema) that is controlled by systemic treatments (like pills or injections) use and feel about a cosmetic moisturizer called RV4427C WM0071. The goal was to understand their needs, expectations, and how s…

This study looked at 80 adults with moderate-to-severe atopic dermatitis (eczema) whose condition is controlled by systemic treatments. Researchers wanted to understand how these patients use moisturizers and what they expect from them. Participants filled out questionnaires abou…

This study looked at 100 adults with atopic dermatitis (eczema) who were prescribed tralokinumab. Researchers tracked how many developed eye problems like conjunctivitis within 4 months of starting the drug. The goal was to better understand these side effects in real-world use, …

This study looked at how a new drug called amlitelimab affects the way the body processes other medications in adults with moderate-to-severe atopic dermatitis (eczema). 23 participants received amlitelimab and a cocktail of common drugs to measure changes in drug levels. The goa…

This early-stage study tested a single dose of the experimental antibody SM17 in 30 healthy Chinese adults to see if it is safe and how the body processes it. The study did not aim to treat any disease. Results will help plan future trials for conditions like eczema, asthma, and …

This study looked at skin samples from 170 people with psoriasis, atopic dermatitis (eczema), or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn activity and related enzymes in both affected and unaffected skin. The goal w…

This study followed 487 pregnant women in Shanghai to see if key nutrients like folate and vitamin D affect the chance of their baby developing eczema (atopic dermatitis) by 6 months old. Researchers measured nutrient levels in the mothers' blood and checked babies for eczema usi…

This study looked at the types of fungi living on the head and neck skin of 30 adults with eczema (atopic dermatitis) compared to healthy volunteers. The goal was to understand if differences in the fungal community are linked to eczema in these areas. Researchers used advanced l…

This study looked at whether the drug dupilumab, used for eczema or asthma, is safe during pregnancy. Researchers compared 581 pregnant women who took dupilumab with those who did not. They tracked birth defects, miscarriages, and infant health up to one year old to see if the dr…

This study looked at the safety and effectiveness of the eczema drug upadacitinib in teenagers aged 12 to under 18 in Japan. About 170 teens who were already prescribed the drug by their doctor took part. Researchers collected data from regular clinic visits and questionnaires ov…

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…

This study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to ident…

This completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…

This study tested how well the body absorbs rocatinlimab, a drug for atopic dermatitis (eczema), when given through an autoinjector pen compared to a traditional vial and syringe. It involved 231 healthy adults aged 18-60. The goal was to see if the autoinjector delivers the drug…

This study tested a new way to collect fluid from the skin using a tiny microneedle patch. Researchers compared samples from 20 healthy volunteers and people with eczema (atopic dermatitis) to see how much fluid could be collected and how well it was tolerated. The goal was to le…

This early-phase study tested a single dose of the experimental drug rocatinlimab in 20 healthy Chinese adults. The main goal was to see how the drug moves through the body and whether it is safe. This is a first step toward possibly using the drug to treat atopic dermatitis (ecz…

This study looked at how staphylococcus bacteria on the skin affect inflammation and immune responses in people with moderate to severe atopic dermatitis (eczema). Researchers took skin biopsies and blood samples from 41 adults to measure bacterial toxins and immune cell activity…

This study tested how the body absorbs rocatinlimab, a potential eczema treatment, when given through a vial versus a prefilled syringe. 240 healthy adults received a single dose to compare the two methods. The goal was to see if the syringe works as well as the vial, not to trea…

This early-phase study looked at how rocatinlimab, an experimental drug for eczema, affects the way the body processes several common medications (caffeine, metoprolol, midazolam, warfarin, omeprazole). 21 adults with moderate to severe eczema took these drugs with and without ro…

This study followed 461 children whose mothers took a special nutritional drink before and during pregnancy. Researchers want to understand how parents' diet, lifestyle, and metabolism influence child growth, thinking skills, and overall well-being. The goal is to identify factor…

This study looked at how an experimental medicine called PF-08049820 moves through the body when taken in different forms (fast-release and slow-release tablets) and with or without food. Twelve healthy adults each tried five versions of the medicine, with blood samples taken for…

This study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effec…

This study looked at how dupilumab, an injectable eczema drug, changes nerve fibers in the skin of 54 adults with moderate-to-severe atopic dermatitis and chronic itching. Researchers took skin biopsies to measure nerve density and branching before and after treatment. The goal w…

This completed study looked at how a common skin bacterium, Staphylococcus aureus, might cause eczema flares in people with atopic dermatitis. Researchers applied patches containing the bacteria to the skin of 7 participants (both with and without eczema) and measured immune resp…